Cannvas MedTech (CSE:MTEC), a leading digital cannabis educator and business technology company, is pleased to announce its plans to form an independent panel of esteemed and established scientific consultants from across a range of industries to provide oversight and original content to the Cannvas.Me digital cannabis education platform. Members of the newly-formed Cannabis Sciences Advisory Board are expected to be announced in early 2019.
“We are excited to bring together scientific experts from within and outside the cannabis industry to contribute their wealth of knowledge and experience in ensuring the educational content on Cannvas.Me remains relevant as it pertains to the latest in cannabis and health sciences,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “As researchers continue to unravel the science of cannabis and solve new and potentially industry-disrupting mysteries surrounding the plant and its uses – such as the developing argument of classifying cannabis by terpene profiles instead of strain names – our Cannabis Sciences Advisory Board will help ensure Cannvas.Me users continue to receive up-to-date research-based information in an easy-to-learn format.”
The newly-formed Cannabis Sciences Advisory Board joins the independent Medical Advisory Board and Educational Advisory Panel already established at Cannvas.Me. The two existing boards are made up of licenced health practitioners and certified educators from Canada and the United States. The Cannabis Sciences Advisory Board will also include prominent Canadians and Americans who are among the leaders in their fields with robust backgrounds in education, health sciences, medicine and research. Members of the Board will be in constant communication with the Cannvas.Me team to offer guidance on new educational modules, oversight of and contributions to original Cannvas.Me content, and insights into health sciences, clinical trials, medical and scientific regulatory affairs, and other related topics.
“The cannabis industry is growing like a weed and a constant stream of conflicting facts and misinformation from a range of unreliable sources underscores the crucial need for scientific evidence to support the evolving narrative of this complex plant,” said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech Inc. “The addition of a Cannabis Sciences Advisory Board allows Cannvas.Me to provide its users with an accessible and elevated educational experience based on the latest meaningful and evidence-based research being done in the science community across Canada and the world.”
Operating independent of any licenced producers or clinics, Cannvas.Me works with its Medical Advisory Board and Educational Advisory Panel to provide a safe space for cannabis education with no pressure to purchase or consume. The Cannabis Sciences Advisory Board will work toward the same goal and strive to ensure all original content relating to health and cannabis sciences is delivered to users in an accurate and relevant fashion in easily-digestible educational modules.
Aiming to be the household name in cannabis education, Cannvas.Me provides free and physician-backed digital cannabis education for all audiences wishing to learn about the potential health benefits of cannabis and whether it fits their lifestyle. The educational platform features a number of innovative modules and tools making cannabis education approachable and accessible to a global audience:
- Cannvas Academy – educational learning modules created by licensed medical practitioners and certified educators with a focus on health care, lifestyle and wellness;
- Cannvas Strain Matcher – an interactive experience where users learn which strain is best for alleviating specific ailments;
- Cannvas Culinary – a culinary training module with recipes, ideas and more;
- Cannvas Health & Fitness – combining a cannabis-healthy lifestyle with training and fitness activities;
- Cannvas Cannabis & Science – for active and potential cannabis users interested in learning more about the science of the plant and how it impacts the human endocannabinoid system.
Additionally, the company has granted incentive stock options to purchase a total of 1,500,000 common shares at an exercise price of $0.28 per share for a period of five years to certain directors and officers in accordance with the provisions of its stock option plan.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
For further information: Investor Relations: Renmark Financial Communications Inc., Shushu Feng: email@example.com, Tel: (416) 644-2020 or (212) 812-7680, CannvasMedTech.com
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact firstname.lastname@example.org, or